Reshmi Nair - Biofus Therapeut Ltd | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 13 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Co-inhibition of TGF-β and PD-L1 Pathways in a Metastatic Colorectal Cancer Mouse Model Triggers Interferon Responses, Innate Cells and T Cells, Alongside Metabolic Changes and Tumor Resistance

Reshmi Nair,Tamsin R. M. Lannagan,Rene Jackstadt,Anna Andrusaite,John Cole, Caitlin Boyne,Robert J. B. Nibbs,Owen J. Sansom,Simon Milling

ONCOIMMUNOLOGYno. 1 (2024)

引用0浏览0WOS引用

Abstract 1864: An improved trispecific antibody (TsAb) platform for optimally engaging T cells for the treatment of solid tumor malignancies

Reshmi Nair,Veena Somasundaram, Arvind Goswami,Jaya Bhatnagar, Sourav Paul,Chaitali Dey, Kalyan Vaidyanathan,Rajkumar Paul, Sankar Periasamy,M. McGettrick Helen, Mahalakshmi NV,Abhishek Sinha,Rachel Salazar, Ankur Nandan Varshney

Cancer Researchno. 7_Supplement (2023): 1864-1864

引用0浏览0引用

1426 Combination with BCA101 improves the efficacy of KRAS-G12C inhibitor and overcomes G12C inhibitor-induced resistance in lung and colon cancer cell lines

Rachel Salazar,Reshmi Nair,Pradip Nair,Veena Somasundaram,Shiv Ram Krishn

Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)

引用0浏览0引用

Real World Outcomes of Next Generation Sequencing (NGS) of Progressive RAI Resistant Metastatic Thyroid Cancer and Treatment of These Patients with Redifferentiation Protocol

Jennifer Wheeley,Nikita Chintapally,Kanchan Kulkarni,Reshmi Nair,Priya Kundra,Jennifer Rosen,Meeta Sharma,Jason Wexler,Kenneth D. Burman,Leila Shobab,Irina Veytsman

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

An improved trispecific antibody (TsAb) platform for optimally engaging T cells for the treatment of solid tumor malignancies

Reshmi Nair,Veena Somasundaram, Arvind Goswami,Jaya Bhatnagar, Sourav Paul,Chaitali Dey, Kalyanaraman Vaidyanathan,Rajkumar Paul, Sankar Periasamy, Mary Helen Kg, Mahalakshmi Nv,Abhishek Sinha,Rachel Salazar, Avanish K. Varshney

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

Abstract 6339: BCA101, a Novel Tumor-Targeted Bifunctional Fusion Antibody Simultaneously Inhibiting EGFR and TGF-β Signaling with Potential for Durable Tumor Growth Inhibition

Srinivas Reddy Boreddy,Reshmi Nair,Prashant Kumar Pandey,Anshu Kuriakose,Arindam Banerjee,Chaitali Dey, A R Madhukara,Bhadravathi Marigowda Shivakumar,Hanumant Kulkarni,Milind Sagar, Popovic Z.V.,Shiv Ram Krishn,Jaya Bhatnagar,Moni Abhram Kuriakose,Ram Bhupal Reddy,Amritha Suresh,Praveen Reddy Moole,Usha Bughani,Seng-Lai Tan,Pradip Nair,Rachel Salazar

Cancer researchno. 7_Supplement (2023): 6339-6339

引用0浏览0引用

A novel bispecific bca356 targeting tumour antigen caix conjugated to an attenuated il12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity

Pradip Nair,Arvind Goswamy,Jaya Bhatnagar,Srinivas Boreddy,Reshmi Nair,Shiv Krishn,Anshu Kuriakose,Prashanth Pandey,Hanumant Kulkarni,Kishore Punnath,Milind Sagar,V Prashanthakumara,T. K. Thulsi,Abhishek Sinha,D. R. Ravindra,Rachel Salazar

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022): A1419-A1420

引用0浏览0引用

874 Development of BCA101, a Bifunctional Antibody Capable of Simultaneously Disabling EGFR and TGFβ Signaling, As Novel Single-Agent Immunotherapy

Srinivas Reddy Boreddy,Raji R. Nair,Arindam Banerjee,Anshu Kuriakose,Prashant Pandey,Chaitali Dey,Meena Shri,Shruthi Rao,Bhadravathi Marigowda Shivakumar,Moni Abhram Kuriakose,Ram Bhupal Reddy,Amritha Suresh,Praveen Reddy Moole,Usha Bughani,Seng‐Lai Tan,Pradip Nair

Regular and Young Investigator Award Abstracts（2021）

引用2浏览0引用

T Cell Activation And Differentiation Is Modulated By A Cd6 Domain 1 Antibody Itolizumab (Vol 12, E0180088, 2017)

Usha Bughani,Arindam Saha,Anshu Kuriakose,Reshmi Nair,Ravindra B. Sadashivarao,Rasika Venkataraman,Swati Patel,Anuja Tushar Deshchougule,Kumar S. Satish,Enrique Montero,Harish Venkatraman Pai,Dinesh V. Palanivelu,Ramakrishnan Melarkode,Pradip Nair

PLOS ONE（2018）

引用30浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn